Proglumide is primarily used in medical and pharmacological research due to its role as a cholecystokinin (CCK) receptor antagonist. It has been studied for its potential to modulate gastrointestinal functions, particularly in managing conditions like gastritis, peptic ulcers, and pancreatitis, where CCK plays a significant role. Additionally, proglumide has been explored for its neuroprotective effects, showing promise in reducing pain and inflammation in conditions such as neuropathy and fibromyalgia. Its ability to block CCK receptors also makes it a candidate for research in anxiety and depression, as CCK is involved in stress responses. Furthermore, proglumide has been investigated for its potential to enhance the efficacy of certain chemotherapeutic agents in cancer treatment by reducing drug resistance.